Skip to main content

Table 1

From: Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab

  Median OS, mo (95% CI) OS rate, % (95% CI)
   1-yr 2-yr
Treatment group    
 0.3 mg/kg (n=22) 16.4 (10.1-NR) 71 (47-86) 44 (22-64)
 2.0 mg/kg (n=22) NR 72 (48-86) 61 (36-78)
 10 mg/kg (n=23) 25.2 (12.0-NR) 74 (48-88) 51 (27-71)
 10 mg/kg (naïve) (n=24) NR 81 (57-92) 76 (51-89)
PD-L1 expression    
 ≥5% (n=18) NR 71 (44-87) 64 (37-82)
<5% mg/kg (n=38) 23.4 (13.1-33.3) 71 (52-83) 48 (30-64)
  1. NR = not reached